The in-vitro activity of trovafloxacin and nine other antimicrobials against 413 anaerobic bacteria | Zendy

Karen E. Bowker | Zendy; Mandy Wootton | Zendy; H. A. Holt | Zendy; D. S. Reeves | Zendy; Alasdair MacGowan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The in-vitro activity of trovafloxacin and nine other antimicrobials against 413 anaerobic bacteria

Author(s) -

Karen E. Bowker,

Mandy Wootton,

H. A. Holt,

D. S. Reeves,

Alasdair MacGowan

Publication year - 1996

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/38.2.271

Subject(s) - trovafloxacin , microbiology and biotechnology , anaerobic bacteria , clindamycin , imipenem , bacilli , antimicrobial , antibacterial agent , peptostreptococcus , agar dilution , chemistry , medicine , minimum inhibitory concentration , antibiotics , pharmacology , biology , bacteria , antibiotic resistance , genetics

The in-vitro activity of trovafloxacin and nine other antimicrobials was determined for 413 non copy anaerobic clinical isolates. Trovafloxacin was the most active quinolone tested with an MIC90 of 0.5 mg/L against Gram-positive cocci (n = 75); MIC90 of 4 mg/L against Gram-positive bacilli (n = 151); MIC90 of 0.5 mg/L for Gram-negative cocci (n = 12) and MIC90 of 1 mg/L for Gram-negative bacilli (n = 175). Overall the MIC90 of trovafloxacin was 1 mg/L which was equivalent to co-amoxiclav and one dilution higher than that of imipenem. The other seven comparators, including clindamycin and metronidazole, had higher MIC90 values than trovafloxacin. Trovafloxacin is likely to have clinically useful activity against anaerobes from human infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research